Saturday 17 October 2026
Export AKTX’s income statement to Excel — free account
Akari Therapeutics PLC
AKTX Healthcare Biotechnology
In the quarter to June 2026, EPS fell 60.3%, free cash flow grew 4.51% and total debt fell 1.00%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
8.18
0.66
−7.47%
Follow AKTX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
0.60 | 0.27 | 0.44 | 0.19 |
+8 more quarters Free account |
Net Debt/EBITDA |
1.53 | 0.18 | 1.42 | 0.25 | |
Debt/Assets |
1.79% | 0.00% | 1.41% | 1.46% | |
Debt/Equity |
0.04 | 0.00 | 0.02 | 0.03 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.65 | 0.17 | 0.57 | 0.33 | |
Interest Coverage |
(57.52) | (258.33) | (4.46) | (61.19) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.78 | 0.89 | 0.89 | 0.94 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(1.74) | (1.68) | (3.61) | (2.60) | |
Cash per Share |
4.33 | 1.91 | 6.25 | 3.12 | |
Shareholders Equity per Share |
10.38 | 9.69 | 33.66 | 27.78 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
10.38 | 9.69 | 33.66 | 27.78 | |
Free Cash Flow |
(3.11) | (2.49) | (3.04) | (2.12) | |
Working Capital |
(5.61) | (9.83) | (6.89) | (12.62) | |
Net Current Asset Value |
(11.70) | (15.92) | (14.10) | (19.74) | |
| Other line items | |||||
Quick Ratio |
0.56 | 0.21 | 0.43 | 0.16 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.74) | (1.68) | (3.61) | (2.60) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
10.50 | 10.85 | 10.59 | 7.81 | |
Average Assets |
44.77 | 42.42 | 49.23 | 24.06 | |
Average Common Equity |
22.10 | 18.06 | 25.28 | 8.00 |
Columns are period end dates